Imaging Mitochondrial Complex-I in Cocaine Use Disorder: a [F-18]BCPP-EF PET Study

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-45
SponsorRajesh Narendran

About this trial

Studies proposed in this application will image mitochondrial Complex-I in cocaine use disorder (CUD) and matched healthy controls

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Males or females between 18 and 45 years old.

fulfill DSM-5 criteria for moderate or severe (4+ criteria) cocaine use disorder.

No lifetime DSM-5 schizophrenia, schizoaffective disorder, bipolar disorder, and developmental disorders.

No comorbid DSM-5 major depressive or severe anxiety disorders (including cocaine-induced mood and anxiety disorders) in the past 12 months.

Disqualifiers

None

Trial design

Design model

Single group

Treatments tested in this trial

  • [F-18]BCPP-EF

    Drug

    Radiotracer

Treatment groups

40 Participants
are divided into 1 treatment group
Group A: PETExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Orbitofrontal Cortex [F-18]BCPP-EF VT

VT is the volume of distribution expressed relative to total plasma radioligand concentration

Time frame
Baseline scan (time 0)
2

Midbrain [F-18]BCPP-EF VT

VT is the volume of distribution expressed relative to total plasma radioligand concentration

Time frame
Baseline scan (time 0)
3

Ventral Striatum [F-18]BCPP-EF VT

VT is the volume of distribution expressed relative to total plasma radioligand concentration

Time frame
Baseline scan (time 0)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Rajesh Narendran

Lead sponsor

University of Pittsburgh

Sponsor institution

National Institute on Drug Abuse (NIDA)

Collaborator